[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536250":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":20,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient at risk for disease relapse after surgery","EXPERIMENTAL","1. we utilized a relapse prediction model that combined perioperative variation trends of circulating tumor cells and pathologic characteristics that were collated with relapse\n\n   1. circulating tumor cell variation trend: difference between the CTC count on post-operation day 3 and day 1; difference between the CTC count on post-operation day 3 and post-operation\n   2. pathologic staging 0-1a\u002F 1b-4\n2. patient with high relapse for relapse\n\n   * Adjuvant was recommended as NCCN guidelines recommended",[13],"Drug: Cisplatin based chemottherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cisplatin based chemottherapy","adjuvant therapy for high risk patient",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Ching-Yang Wu","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+886975368204","wu.chingyang@gmail.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Chia-Tsun CH Hsieh","-886975366137","wisdom5000@gmail.com",[35],{"facility":23,"status":36,"city":37,"state":20,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Taoyuan City","333","Taiwan","TW",{"type":42,"coordinates":43},"Point",[44,45],121.29696,24.99368,{"lat":45,"lon":44},[48,49,52,55],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":50,"role":27,"phone":51,"phoneExt":20,"email":33},"Jason CH Hsieh","+886975366137",{"name":53,"role":54,"phone":20,"phoneExt":20,"email":20},"Jui-Ying Fu","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":20,"phoneExt":20,"email":20},"Ching-Feng Wu",{"type":58,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[60],{"name":61,"class":62},"National Science and Technology Council","FED","100536250","combined-relapse-prediction-model-for-resectable-non-small-cell-patients---a-prospective-clinical-feasibility-trial-100536250",false,"NCT06262386","Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial","Utilizing Perioperative Variation Trends of Circulating Tumor Cells and Tumor Pathological Characteristics as a Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial","Inclusion Criteria:\n\n1. Patients who presented with resectable disease ( Clinical stage 1a to 3a)\n2. Patients who received tumor resection\n\nExclusion Criteria:\n\n1. Pathologic stage greater than stage 3b or 4\n2. Pathologic stage less than stage 1a1\n3. Could not complete treatment course\n4. Could not receive blood sampling for CTC (circulating tumor cell) or regular surveillance","ALL","20 Years","90 Years",{"count":74,"type":75},358,"ESTIMATED","INTERVENTIONAL",[78],"NA","For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early relapse. To address this clinical challenge, many studies have focused on understanding the clinicopathologic characteristics associated with an increased risk of early relapse. Despite these efforts, we can identify patients at risk but cannot pinpoint which individuals will actually experience early relapse. Studies on adjuvant therapy have shown improved survival in cases of more advanced disease but have not demonstrated a reduction in early relapse rates.\n\nIn our preliminary analysis of previous study data, we observed that patients with a smaller reduction in circulating tumor cells (CTCs) within the first three days after surgery, followed by an increase on the third-day post-operation, are more likely to experience early relapse during regular monitoring. This pattern may be indicative of minimal residual disease. By combining trends in circulating tumor cell variations with pathologic characteristics, we aim to select patients for adjuvant therapy who are at high risk of developing early relapse.\n\nThe objective of our study is to employ screening based on circulating tumor cell dynamics and pathologic features to identify patients likely to experience early relapse and to assess the effectiveness of adjuvant therapy in these cases.",[81,82],"Lung Cancer","Relapse\u002FRecurrence",[84,85,86],"Circulating tumor cell","resectable non-small cell lung cancer","Early relapse","2024-02-07",{"date":89,"type":90},"2024-02-16","ACTUAL",{"date":92,"type":90},"2023-08-01",{"date":94,"type":75},"2028-07-31",{"name":5,"class":6},1]